Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

Next Previous
X
Search
Trial Profile

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Sonrotoclax (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BeiGene

    • Most Recent Events

    • 07 Aug 2024 According to BeiGene media release, the company has presented the results of Phase 1 trials demonstrating encouraging response rates, durable responses and manageable safety profiles in combination with dexamethasone in R/R multiple myeloma harboring translocation, at EHA 2024.
    • 12 Dec 2023 Results assessing the overall safety/tolerability profile as well as determine the MTD / MAD and establish the phase2 RP2D of sonrotoclax as monotherapy, in combination with dexamethasone, or in combination with dexamethasone plus carfilzomib in patients with R/R MM, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 13 Dec 2022 Preliminary safety results (at data cutoff: 1 July 2022; n=10) presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top